Making a Difference, Here & Beyond
The community invests in Dell Med. In return, it’s our responsibility — one we take seriously — to be agents for change and to show real impact.
More Information
Creating a New Kind of Doctor
We recruit and train physician leaders as comfortable taking on systemic challenges in health as caring for individual patients.
Improving Care. Improving Health.
We’re here to make health — including health care — better. The end goal is a complete revolution in how people get and stay healthy.
Discovery to Impact — Faster
We reward creative thinking and encourage rapid experimentation, using collaborative programs to speed promising research to market.
More Information
Let’s Do Big Things Together
True health demands that the whole work in harmony, which is why we’re dedicated to partnership. Indeed, we can’t achieve our goals without it.
More Information
Meet Dell Med
We’re rethinking the role of academic medicine in improving health — and doing so with a unique focus on our community.
More Information
Make an Appointment Directory Give Faculty Students

Management of Treatment-Resistant Depression

Location: Zoom

Date: Tuesday, September 29, 2020

Time: 12–1 p.m.

Contact: Renee Collins

About the Event

Join us for the next installment of Psychiatry Grand Rounds featuring Samuel Collier, M.D., presenting “Management of Treatment Resistant Depression.” Collier is an associate professor in the Department of Psychiatry and Behavioral Sciences and director of the Treatment-Resistant Depression Integrated Practice Unit at UT Health Austin.

Email Renee Collins to obtain the Zoom meeting information.

Learning Objectives

By the end of this presentation, the audience participant should be able to:

  • Define treatment resistant depression (TRD);
  • Discuss the social and economic burden of TRD;
  • Identify the top three evidence-based augmentation strategies to antidepressants;
  • Discuss concerns about esketamine as the newest FDA-approved medication for TRD.

Target Audience

  • Primary: Psychiatrists, social workers, psychologists, nurses and other mental health professionals
  • Secondary: Other health care professionals


This activity has been designed to promote some of the following desired physician attributes and competencies:

  • ACGME: Patient care; medical knowledge; practice-based learning and improvement; interpersonal and communication skills; professionalism; systems-based practice.
  • IOM: Provide patient-centered care; work in interdisciplinary teams; employ evidence-based practice; apply quality improvement; utilize informatics.
  • IECC: Interprofessional teamwork and team-based practice; interprofessional communication; values and ethics for interprofessional practice.

Collier has no relevant financial relationships to disclose relating to the educational content of this presentation.

The Dell Medical School Department of Psychiatry and Behavioral Sciences Grand Rounds planning committee members are Robert E. Feinstein, M.D.; Charles Nemeroff, M.D., Ph.D.; Roshni Koli, M.D.; Jorge Almeida, M.D., Ph.D.; Jeff Newport, M.D.; Steve Strakowski, M.D.; Lowell McRoberts, M.D.; Cathy Stacy, Ph.D.; Kathryn Flowers; and Renee Collins.

Jeff Newport, M.D., reported the following relevant financial relationships:

  • Grants/Research support: Eli Lilly, Glaxo SmithKline (GSK), Janssen, National Alliance for Research on Schizophrenia and Depression (NARSAD), National Institutes of Health (NIH), Sage Therapeutics, Takeda Pharmaceuticals, Texas Health & Human Services Commission, Wyeth.
  • Honorarium: Astra-Zeneca, Eli Lilly, GSK, Pfizer, Wyeth.
  • Speaker’s Bureau: Astra-Zeneca, Eli Lilly, GSK, Pfizer, Wyeth.
  • Other (please describe): Advisory Boards: GSK, Janssen, Sage Therapeutics.

Steve Strakowski, M.D., reported the following relevant financial relationships:

  • Grants/Research support: Janssen.
  • Consultant: Sunovion (Data & Safety Monitoring Board Chair), Otsuka (Data Monitoring Committee member).
  • Honorarium: Medscape.

Charles B. Nemeroff, M.D., Ph.D. reported the following relevant financial relationships:

  • Grants/Research support: National Institutes of Health (NIH).
  • Consultant: Xhale, Takeda, Taisho Pharmaceutical Inc. Signant Health, Sunovion Pharmaceuticals Inc., Janssen Research & Development LLC, Magstim, Inc., Navitor Pharmaceuticals, Inc., TC MSO, Inc., Intra-Cellular Therapies, Inc., EMA Wellness, Gerson Lehrman Group (GLG), Acadia Pharmaceuticals.
  • Stock shareholder (directly purchased): Xhale, Celgene, Seattle Genetics, Abbvie, OPKO Health, Inc., Antares, BI Gen Holdings, Inc., Corcept Therapeutics Pharmaceuticals Company, TC MSO, Inc., Trends in Pharma Development, LLC, EMA Wellness.
  • Honorarium: various universities for Grand Rounds.
  • Board of Directors or other leadership role: Gratitude America, ADAA, Xhale Smart, Inc.
  • Other (Please describe): American Psychiatric Publishing, Xhale, Signant Health, CME Outfitters, Intra-Cellular Therapies, Inc., Magstim, EMA Wellness Patents: Method and devices for transdermal delivery of lithium (US 6,375,990B1) Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2) Compounds, Compositions, Methods of Synthesis, and Methods of Treatment (CRF Receptor Binding Ligand) (US 8,551, 996 B2).

The other planners have no relevant financial relationships to disclose relating to the educational content of this series.

Accreditation Statement:

The University of Texas at Austin Dell Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas at Austin Dell Medical School designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.